Soligenix announced that it will present the results of its HyBryte study at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop scheduled for March 26 2026, following the company’s March 23 2026 announcement.
HyBryte is a synthetic hypericin‑based photodynamic therapy that uses visible light to treat cutaneous T‑cell lymphoma (CTCL). The presentation will compare HyBryte’s efficacy and safety to Valchlor (mechlorethamine), a standard topical chemotherapy. Dr. Ellen Kim, principal investigator for the FLASH and FLASH2 studies, and Dr. Brian Poligone, who is leading the HyBryte versus Valchlor study, will deliver the data.
The data are significant because HyBryte has received orphan drug and fast‑track designations from the U.S. Food and Drug Administration and orphan status from the European Medicines Agency. The presentation is part of Soligenix’s strategy to support regulatory approval and to position HyBryte as a potential first‑line therapy for CTCL. The company is also advancing its second confirmatory Phase 3 trial, FLASH2, with an interim analysis expected in the second quarter of 2026.
In the broader therapeutic landscape, Citius Oncology’s LYMPHIR (denileukin diftitox‑cxdl) was launched in December 2025 for relapsed or refractory CTCL, underscoring the competitive environment. Soligenix’s pipeline also includes candidates for psoriasis, inflammatory diseases, and Behçet’s disease, as well as a public‑health solutions segment focused on biodefense vaccines.
Financially, Soligenix has reported significant net losses and a cash balance of approximately $10.5 million as of September 30 2025. The company’s Q4 2025 earnings are scheduled for March 31 2026. Despite the cash constraints, CEO Christopher J. Schaber has expressed confidence in the company’s late‑stage rare‑disease pipeline and upcoming milestones, including the HyBryte Phase 3 results.
No specific market reaction has been reported following the announcement. Analysts have expressed a range of views on the company’s prospects, reflecting the uncertainty inherent in late‑stage clinical development and the company’s financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.